Login to Your Account



AACR Annual Meeting

Phase III Biomarker Data Predict Advexin Efficacy in Some Patients

By Donna Young


Tuesday, April 15, 2008
Introgen Therapeutics Inc. said that preliminary data of a Phase III trial showed that Advexin, an investigational therapy that targets the abnormal p53 tumor suppressor function, which is associated with cancer initiation, progression and treatment resistance, significantly increased the survival of patients with head and neck cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription